Gantenerumab

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals.^[1][2]

Gantenerumab

Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green). PDB: 5CSZ​.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Beta-amyloid (Aβ40/42)
Clinical data
ATC code	none
Legal status
Legal status	Investigational
Identifiers
CAS Number	1043556-46-2 N
ChemSpider	none
UNII	4DF060P933
KEGG	D09680 Y
Chemical and physical data
Formula	C6496H10072N1740O2024S42
Molar mass	146276.71 g·mol−1
NY (what is this?)  (verify)

Gantenerumab binds to and clears aggregated beta amyloid fibers.^[3]

A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy.^[4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease^[5] but after five years of treatment, the drug did little to slow cognitive decline in patients.^[6]

A study published in 2025 suggests that Gantenerumab appears to reduce the risk of Alzheimer's-related dementia in people with rare genetic mutations mutations that cause the overproduction of amyloid in the brain. These people are normally destined to develop the disease in their 30s, 40s or 50s.^[7]

Gantenerumab has been further developed into trontinemab, which started a Phase III trial in 2025. Trontinemab consists of gantenerumab fused to Roche's proprietary Brainshuttle module to help it cross the blood–brain barrier.^[8]